{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:15:32Z","timestamp":1794964532491,"version":"4.9.1"},"reference-count":278,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1038\/s41581-026-01125-6","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:04:03Z","timestamp":1790611443000},"page":"880-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the aldosterone\u2013mineralocorticoid receptor pathway in cardiovascular\u2013kidney\u2013metabolic syndrome"],"prefix":"10.1038","volume":"22","author":[{"given":"Tania","family":"S\u00e1nchez-Bayuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-5092","authenticated-orcid":false,"given":"Jonatan","family":"Barrera-Chimal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9051-1901","authenticated-orcid":false,"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1016\/j.ekir.2024.05.033","volume":"9","author":"ZA Massy","year":"2024","unstructured":"Massy, Z. A. & Drueke, T. B. Combination of cardiovascular, kidney, and metabolic diseases in a syndrome named cardiovascular-kidney-metabolic, with new risk prediction equations. Kidney Int. Rep. 9, 2608\u20132618 (2024).","journal-title":"Kidney Int. Rep."},{"key":"1125_CR2","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele, C. E. et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation 148, 1636\u20131664 (2023).","journal-title":"Circulation"},{"key":"1125_CR3","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/j.2040-4603.2014.tb00565.x","volume":"4","author":"WB Bollag","year":"2014","unstructured":"Bollag, W. B. Regulation of aldosterone synthesis and secretion. Compr. Physiol. 4, 1017\u20131055 (2014).","journal-title":"Compr. Physiol."},{"key":"1125_CR4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1161\/01.HYP.0000175814.18550.c0","volume":"46","author":"C Xue","year":"2005","unstructured":"Xue, C. & Siragy, H. M. Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46, 584\u2013590 (2005).","journal-title":"Hypertension"},{"key":"1125_CR5","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1046\/j.1523-1755.2000.00973.x","volume":"57","author":"C Delcayre","year":"2000","unstructured":"Delcayre, C. et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int. 57, 1346\u20131351 (2000).","journal-title":"Kidney Int."},{"key":"1125_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mce.2003.10.012","volume":"217","author":"Y Takeda","year":"2004","unstructured":"Takeda, Y. Vascular synthesis of aldosterone: role in hypertension. Mol. Cell. Endocrinol. 217, 75\u201379 (2004).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1125_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","volume":"93","author":"HM Siragy","year":"2008","unstructured":"Siragy, H. M. & Xue, C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp. Physiol. 93, 817\u2013824 (2008).","journal-title":"Exp. Physiol."},{"key":"1125_CR8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/hr.2012.224","volume":"36","author":"N Oshima","year":"2013","unstructured":"Oshima, N. et al. Aldosterone is synthesized in and activates bulbospinal neurons through mineralocorticoid receptors and ENaCs in the RVLM. Hypertens. Res. 36, 504\u2013512 (2013).","journal-title":"Hypertens. Res."},{"key":"1125_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones, A. M. et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59, 1069\u20131078 (2012).","journal-title":"Hypertension"},{"key":"1125_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11906-012-0323-2","volume":"15","author":"PC Underwood","year":"2013","unstructured":"Underwood, P. C. & Adler, G. K. The renin angiotensin aldosterone system and insulin resistance in humans. Curr. Hypertens. Rep. 15, 59\u201370 (2013).","journal-title":"Curr. Hypertens. Rep."},{"key":"1125_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14020626","volume":"14","author":"S Rubattu","year":"2025","unstructured":"Rubattu, S., Gallo, G. & Volpe, M. The balance between the natriuretic peptides and the renin-angiotensin-aldosterone system in the preservation of ideal cardiovascular health. J. Clin. Med. 14, 626 (2025).","journal-title":"J. Clin. Med."},{"key":"1125_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/bs.vh.2023.06.002","volume":"124","author":"MB Bauer","year":"2024","unstructured":"Bauer, M. B. & Currie, K. P. M. Serotonin and the serotonin transporter in the adrenal gland. Vitam. Horm. 124, 39\u201378 (2024).","journal-title":"Vitam. Horm."},{"key":"1125_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.787323","volume":"12","author":"AM Zapf","year":"2021","unstructured":"Zapf, A. M., Grimm, P. R., Al-Qusairi, L., Delpire, E. & Welling, P. A. Low salt delivery triggers autocrine release of prostaglandin E2 from the aldosterone-sensitive distal nephron in familial hyperkalemic hypertension mice. Front. Physiol. 12, 787323 (2021).","journal-title":"Front. Physiol."},{"key":"1125_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/endo-117-1-279","volume":"117","author":"WB Campbell","year":"1985","unstructured":"Campbell, W. B. & Gomez-Sanchez, C. E. Absence of prostacyclin involvement in angiotensin-induced aldosterone secretion in rat adrenal cells. Endocrinology 117, 279\u2013286 (1985).","journal-title":"Endocrinology"},{"key":"1125_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/bph.14630","volume":"176","author":"Y Ali","year":"2019","unstructured":"Ali, Y., Dohi, K., Okamoto, R., Katayama, K. & Ito, M. Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: action of tolvaptan via vasopressin V2 receptor-independent pathway. Br. J. Pharmacol. 176, 1315\u20131327 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"1125_CR16","first-page":"359","volume":"10","author":"G Mazzochi","year":"1995","unstructured":"Mazzochi, G., Malendowicz, L. K., Meneghelli, V., Gottardo, G. & Nussdorfer, G. G. In-vitro and in-vivo studies of the effects of arginine-vasopressin on the secretion and growth of rat adrenal cortex. Histol. Histopathol. 10, 359\u2013370 (1995).","journal-title":"Histol. Histopathol."},{"key":"1125_CR17","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"A-C Huby","year":"2015","unstructured":"Huby, A.-C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134\u20132145 (2015).","journal-title":"Circulation"},{"key":"1125_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/652738","volume":"2015","author":"N Mu\u00f1oz-Durango","year":"2015","unstructured":"Mu\u00f1oz-Durango, N. et al. Modulation of immunity and inflammation by the mineralocorticoid receptor and aldosterone. Biomed. Res. Int. 2015, 652738 (2015).","journal-title":"Biomed. Res. Int."},{"key":"1125_CR19","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1749-6632.2000.tb05428.x","volume":"917","author":"AM Judd","year":"2000","unstructured":"Judd, A. M. et al. Possible function of IL-6 and TNF as intraadrenal factors in the regulation of adrenal steroid secretion. Ann. N. Y. Acad. Sci. 917, 628\u2013637 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1125_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1006\/gcen.2000.7458","volume":"118","author":"GB Call","year":"2000","unstructured":"Call, G. B. et al. Bovine adrenal cells secrete interleukin-6 and tumor necrosis factor in vitro. Gen. Comp. Endocrinol. 118, 249\u2013261 (2000).","journal-title":"Gen. Comp. Endocrinol."},{"key":"1125_CR21","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00177.2024","volume":"328","author":"HM Costello","year":"2025","unstructured":"Costello, H. M. et al. Sex differences in the adrenal circadian clock: a role for BMAL1 in the regulation of urinary aldosterone excretion and renal electrolyte balance in mice. Am. J. Physiol. Ren. Physiol. 328, F1\u2013F14 (2025).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"E846","DOI":"10.1152\/ajpendo.2000.279.4.E846","volume":"279","author":"CJ Hanke","year":"2000","unstructured":"Hanke, C. J. & Campbell, W. B. Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen. Am. J. Physiol. Endocrinol. Metab. 279, E846\u2013E854 (2000).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1210\/endo.139.10.6252","volume":"139","author":"CJ Hanke","year":"1998","unstructured":"Hanke, C. J., Drewett, J. G., Myers, C. R. & Campbell, W. B. Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology 139, 4053\u20134060 (1998).","journal-title":"Endocrinology"},{"key":"1125_CR24","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1089\/ars.2011.4176","volume":"17","author":"SB Rajamohan","year":"2012","unstructured":"Rajamohan, S. B., Raghuraman, G., Prabhakar, N. R. & Kumar, G. K. NADPH oxidase-derived H2O2 contributes to angiotensin II-induced aldosterone synthesis in human and rat adrenal cortical cells. Antioxid. Redox Signal. 17, 445\u2013459 (2012).","journal-title":"Antioxid. Redox Signal."},{"key":"1125_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00313","volume":"8","author":"GH Tesch","year":"2017","unstructured":"Tesch, G. H. & Young, M. J. Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front. Pharmacol. 8, 313 (2017).","journal-title":"Front. Pharmacol."},{"key":"1125_CR26","unstructured":"Scott, J. H., Menouar, M. A. & Dunn, R. J. Physiology, Aldosterone (StatPearls, 2023)."},{"key":"1125_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1161\/CIRCRESAHA.120.317424","volume":"127","author":"A Lother","year":"2020","unstructured":"Lother, A. Mineralocorticoid receptors: master regulators of extracellular matrix remodeling. Circ. Res. 127, 354\u2013356 (2020).","journal-title":"Circ. Res."},{"key":"1125_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae346","volume":"18","author":"C El Mouhayyar","year":"2025","unstructured":"El Mouhayyar, C., Chhikara, M., Tang, M. & Nigwekar, S. U. Clinical implications of mineralocorticoid receptor overactivation. Clin. Kidney J. 18, sfae346 (2025).","journal-title":"Clin. Kidney J."},{"key":"1125_CR29","doi-asserted-by":"crossref","unstructured":"Gorini, S., Marzolla, V., Mammi, C., Armani, A. & Caprio, M. Mineralocorticoid receptor and aldosterone-related biomarkers of end-organ damage in cardiometabolic disease. Biomol. 8 (2018).","DOI":"10.3390\/biom8030096"},{"key":"1125_CR30","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/CIRCRESAHA.125.325497","volume":"136","author":"C Juguilon","year":"2025","unstructured":"Juguilon, C., Khosravi, R., Radisic, M. & Wu, J. C. In vitro modeling of interorgan crosstalk: multi-organ-on-a-chip for studying cardiovascular-kidney-metabolic syndrome. Circ. Res. 136, 1476\u20131493 (2025).","journal-title":"Circ. Res."},{"key":"1125_CR31","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/cvr\/cvx097","volume":"113","author":"G Jia","year":"2017","unstructured":"Jia, G., Aroor, A. R. & Sowers, J. R. The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall. Cardiovasc. Res. 113, 1055\u20131063 (2017).","journal-title":"Cardiovasc. Res."},{"key":"1125_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062881","volume":"22","author":"C Lefranc","year":"2021","unstructured":"Lefranc, C., Friederich-Persson, M., Foufelle, F., Nguyen Dinh Cat, A. & Jaisser, F. Adipocyte-mineralocorticoid receptor alters mitochondrial quality control leading to mitochondrial dysfunction and senescence of visceral adipose tissue. Int. J. Mol. Sci. 22, 2881 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR33","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1530\/JOE-18-0163","volume":"238","author":"C Lefranc","year":"2018","unstructured":"Lefranc C., Friederich-Persson M., Palacios-Ramirez R. & Nguyen Dinh Cat A. Mitochondrial oxidative stress in obesity: role of the mineralocorticoid receptor. J Endocrinol. 238, R143-R159 (2018).","journal-title":"J Endocrinol."},{"key":"1125_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.tem.2009.05.006","volume":"20","author":"M-C Zennaro","year":"2009","unstructured":"Zennaro, M.-C., Caprio, M. & F\u00e8ve, B. Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol. Metab. 20, 444\u2013451 (2009).","journal-title":"Trends Endocrinol. Metab."},{"key":"1125_CR35","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1111\/bph.15784","volume":"179","author":"B Schreier","year":"2022","unstructured":"Schreier, B., Zipprich, A., Uhlenhaut, H. & Gekle, M. Mineralocorticoid receptors in non-alcoholic fatty liver disease. Br. J. Pharmacol. 179, 3165\u20133177 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"1125_CR36","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1111\/liv.12794","volume":"35","author":"M Pizarro","year":"2015","unstructured":"Pizarro, M. et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int. 35, 2129\u20132138 (2015).","journal-title":"Liver Int."},{"key":"1125_CR37","doi-asserted-by":"publisher","first-page":"R253","DOI":"10.1152\/ajpregu.00316.2021","volume":"322","author":"J Habibi","year":"2022","unstructured":"Habibi, J. et al. Targeting mineralocorticoid receptors in diet-induced hepatic steatosis and insulin resistance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 322, R253\u2013R262 (2022).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1125_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.563434","volume":"11","author":"N Mu\u00f1oz-Durango","year":"2020","unstructured":"Mu\u00f1oz-Durango, N. et al. A mineralocorticoid receptor deficiency in myeloid cells reduces liver steatosis by impairing activation of CD8+ T cells in a nonalcoholic steatohepatitis mouse model. Front. Immunol. 11, 563434 (2020).","journal-title":"Front. Immunol."},{"key":"1125_CR39","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ady0080","volume":"11","author":"R Melton","year":"2025","unstructured":"Melton, R. et al. Single-cell multiome and spatial profiling reveals pancreas cell type-specific gene regulatory programs of type 1 diabetes progression. Sci. Adv. 11, eady0080 (2025).","journal-title":"Sci. Adv."},{"key":"1125_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1677\/JOE-07-0462","volume":"197","author":"M Koizumi","year":"2008","unstructured":"Koizumi, M. & Yada, T. Sub-chronic stimulation of glucocorticoid receptor impairs and mineralocorticoid receptor protects cytosolic Ca2+ responses to glucose in pancreatic \u03b2-cells. J. Endocrinol. 197, 221\u2013229 (2008).","journal-title":"J. Endocrinol."},{"key":"1125_CR41","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.bbrc.2019.03.149","volume":"512","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Aldosterone induced up-expression of ICAM-1 and ET-1 in pancreatic islet endothelium may associate with progression of T2D. Biochem. Biophys. Res. Commun. 512, 750\u2013757 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1125_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8050674","volume":"8","author":"R Goto","year":"2019","unstructured":"Goto, R. et al. Mineralocorticoid receptor may regulate glucose homeostasis through the induction of interleukin-6 and glucagon-like peptide-1 in pancreatic islets. J. Clin. Med. 8, 674 (2019).","journal-title":"J. Clin. Med."},{"key":"1125_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23168954","volume":"23","author":"AE Igbekele","year":"2022","unstructured":"Igbekele, A. E., Jia, G., Hill, M. A., Sowers, J. R. & Jia, G. Mineralocorticoid receptor activation in vascular insulin resistance and dysfunction. Int. J. Mol. Sci. 23, 8954 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR44","doi-asserted-by":"publisher","first-page":"R276","DOI":"10.1152\/ajpregu.00280.2020","volume":"320","author":"G Jia","year":"2021","unstructured":"Jia, G., Lockette, W. & Sowers, J. R. Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 320, R276\u2013R286 (2021).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1125_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","volume":"91","author":"JM Luther","year":"2014","unstructured":"Luther, J. M. Effects of aldosterone on insulin sensitivity and secretion. Steroids 91, 54\u201360 (2014).","journal-title":"Steroids"},{"key":"1125_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","volume":"12","author":"JM Luther","year":"2022","unstructured":"Luther, J. M. & Fogo, A. B. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis. Kidney Int. Suppl. 12, 63\u201368 (2022).","journal-title":"Kidney Int. Suppl."},{"key":"1125_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg, K. et al. Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE 13, e0193380 (2018).","journal-title":"PLoS ONE"},{"key":"1125_CR48","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1159\/000334961","volume":"2","author":"N Takagi","year":"2012","unstructured":"Takagi, N. et al. Mineralocorticoid receptor blocker protects against podocyte-dependent glomerulosclerosis. Nephron Extra 2, 17\u201326 (2012).","journal-title":"Nephron Extra"},{"key":"1125_CR49","doi-asserted-by":"publisher","first-page":"i29","DOI":"10.1093\/ndt\/gfae241","volume":"40","author":"F Jaisser","year":"2025","unstructured":"Jaisser, F. & Barrera-Chimal, J. Mineralocorticoid receptor antagonism for non-diabetic kidney disease. Nephrol. Dial. Transplant. 40, i29\u2013i36 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1125_CR50","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.kint.2025.07.037","volume":"108","author":"H Lazareth","year":"2025","unstructured":"Lazareth, H. et al. Mineralocorticoid receptor inhibition in parietal epithelial cells prevents focal segmental glomerulosclerosis and crescentic glomerulonephritis. Kidney Int. 108, 1057\u20131072 (2025).","journal-title":"Kidney Int."},{"key":"1125_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11906-010-0175-6","volume":"13","author":"S Shibata","year":"2011","unstructured":"Shibata, S. & Fujita, T. The kidneys and aldosterone\/mineralocorticoid receptor system in salt-sensitive hypertension. Curr. Hypertens. Rep. 13, 109\u2013115 (2011).","journal-title":"Curr. Hypertens. Rep."},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/ajh\/hpae140","volume":"38","author":"ND Camarda","year":"2025","unstructured":"Camarda, N. D. et al. Mineralocorticoid receptor in endothelial cells contributes to vascular endothelial growth factor receptor inhibitor-induced vascular and kidney damage. Am. J. Hypertens. 38, 104\u2013110 (2025).","journal-title":"Am. J. Hypertens."},{"key":"1125_CR53","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","volume":"84","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal, J., Bonnard, B. & Jaisser, F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu. Rev. Physiol. 84, 585\u2013610 (2022).","journal-title":"Annu. Rev. Physiol."},{"key":"1125_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.694758","volume":"12","author":"MF Rossier","year":"2021","unstructured":"Rossier, M. F. The cardiac mineralocorticoid receptor (MR): a therapeutic target against ventricular arrhythmias. Front. Endocrinol. 12, 694758 (2021).","journal-title":"Front. Endocrinol."},{"key":"1125_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1004181","volume":"13","author":"F Zhu","year":"2022","unstructured":"Zhu, F., Li, P. & Sheng, Y. Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy. Front. Pharmacol. 13, 1004181 (2022).","journal-title":"Front. Pharmacol."},{"key":"1125_CR56","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1161\/ATVBAHA.119.312954","volume":"39","author":"ME Moss","year":"2019","unstructured":"Moss, M. E. et al. Endothelial mineralocorticoid receptors contribute to vascular inflammation in atherosclerosis in a sex-specific manner. Arterioscler. Thromb. Vasc. Biol. 39, 1588\u20131601 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1125_CR57","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1248\/bpb.b17-00291","volume":"40","author":"Y Hori","year":"2017","unstructured":"Hori, Y. et al. The aldosterone receptor antagonist eplerenone inhibits isoproterenol-induced collagen-I and 11\u03b2-HSD1 Expression in rat cardiac fibroblasts and the left ventricle. Biol. Pharm. Bull. 40, 1716\u20131723 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"1125_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","volume":"168","author":"D Lavall","year":"2019","unstructured":"Lavall, D. et al. The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling. Biochem. Pharmacol. 168, 173\u2013183 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"1125_CR59","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/FJC.0b013e31828c090e","volume":"61","author":"Q Wang","year":"2013","unstructured":"Wang, Q. et al. Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1\/2 in the genomic pathway. J. Cardiovasc. Pharmacol. 61, 520\u2013527 (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1125_CR60","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","volume":"289","author":"D Lavall","year":"2014","unstructured":"Lavall, D. et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J. Biol. Chem. 289, 6656\u20136668 (2014).","journal-title":"J. Biol. Chem."},{"key":"1125_CR61","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1291\/hypres.31.1811","volume":"31","author":"A Mutoh","year":"2008","unstructured":"Mutoh, A., Isshiki, M. & Fujita, T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens. Res. 31, 1811\u20131820 (2008).","journal-title":"Hypertens. Res."},{"key":"1125_CR62","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1152\/physrev.00020.2012","volume":"93","author":"K Chapman","year":"2013","unstructured":"Chapman, K., Holmes, M. & Seckl, J. 11\u03b2-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol. Rev. 93, 1139\u20131206 (2013).","journal-title":"Physiol. Rev."},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1210\/en.2002-220926","volume":"144","author":"MJ Young","year":"2003","unstructured":"Young, M. J., Moussa, L., Dilley, R. & Funder, J. W. Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11\u03b2-hydroxysteroid dehydrogenase inactivation. Endocrinology 144, 1121\u20131125 (2003).","journal-title":"Endocrinology"},{"key":"1125_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073345","volume":"26","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. Aldosterone-induced transformation of vascular smooth muscle cells into macrophage-like cells participates in inflammatory vascular lesions. Int. J. Mol. Sci. 26, 3345 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184888","volume":"2","author":"J Dutzmann","year":"2017","unstructured":"Dutzmann, J. et al. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS ONE 2, e0184888 (2017).","journal-title":"PLoS ONE"},{"key":"1125_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9080946","volume":"9","author":"C-H Tsai","year":"2021","unstructured":"Tsai, C.-H. et al. Aldosterone excess induced mitochondria decrease and dysfunction via mineralocorticoid receptor and oxidative stress in vitro and in vivo. Biomedicines 9, 946 (2021).","journal-title":"Biomedicines"},{"key":"1125_CR67","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal, R. et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42, 152\u2013161 (2021).","journal-title":"Eur. Heart J."},{"key":"1125_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-024-04103-7","volume":"24","author":"A Elshahat","year":"2024","unstructured":"Elshahat, A. et al. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc. Disord. 24, 489 (2024).","journal-title":"BMC Cardiovasc. Disord."},{"key":"1125_CR69","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/POR.S489802","volume":"16","author":"EL Richard","year":"2025","unstructured":"Richard, E. L. et al. Steroidal mineralocorticoid receptor antagonist side effects and reasons for discontinuation: a patient survey (RELICS-PS). Pragmatic Obs. Res. 16, 121\u2013127 (2025).","journal-title":"Pragmatic Obs. Res."},{"key":"1125_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejim.2021.12.027","volume":"97","author":"P Pardo-Mart\u00ednez","year":"2022","unstructured":"Pardo-Mart\u00ednez, P. et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur. J. Intern. Med. 97, 86\u201394 (2022).","journal-title":"Eur. J. Intern. Med."},{"key":"1125_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-019-0924-0","volume":"21","author":"AA Manolis","year":"2019","unstructured":"Manolis, A. A., Manolis, T. A., Melita, H. & Manolis, A. S. Eplerenone versus spironolactone in resistant hypertension: an efficacy and\/or cost or just a men\u2019s issue? Curr. Hypertens. Rep. 21, 22 (2019).","journal-title":"Curr. Hypertens. Rep."},{"key":"1125_CR72","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","volume":"157","author":"RAP Weir","year":"2009","unstructured":"Weir, R. A. P. et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am. Heart J. 157, 1088\u20131096 (2009).","journal-title":"Am. Heart J."},{"key":"1125_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","volume":"107","author":"JP Ferreira","year":"2018","unstructured":"Ferreira, J. P. et al. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER study. Clin. Res. Cardiol. 107, 49\u201359 (2018).","journal-title":"Clin. Res. Cardiol."},{"key":"1125_CR74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/ajh\/hpw105","volume":"30","author":"T Dudenbostel","year":"2017","unstructured":"Dudenbostel, T. & Calhoun, D. A. Use of aldosterone antagonists for treatment of uncontrolled resistant hypertension. Am. J. Hypertens. 30, 103\u2013109 (2017).","journal-title":"Am. J. Hypertens."},{"key":"1125_CR75","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","volume":"79","author":"Y Maeoka","year":"2022","unstructured":"Maeoka, Y. et al. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension 79, 1423\u20131434 (2022).","journal-title":"Hypertension"},{"key":"1125_CR76","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70065","volume":"48","author":"M Ahmed","year":"2025","unstructured":"Ahmed, M. et al. Cardiovascular efficacy and safety of finerenone: a meta-analysis of randomized controlled trials. Clin. Cardiol. 48, e70065 (2025).","journal-title":"Clin. Cardiol."},{"key":"1125_CR77","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"1125_CR78","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos, G. et al. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur. Heart J. 37, 2105\u20132114 (2016).","journal-title":"Eur. Heart J."},{"key":"1125_CR79","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jamacardio.2025.1101","volume":"10","author":"MA Pabon","year":"2025","unstructured":"Pabon, M. A. et al. Finerenone in heart failure with improved ejection fraction: the FINEARTS-HF randomized clinical trial. JAMA Cardiol. 10, 740\u2013745 (2025).","journal-title":"JAMA Cardiol."},{"key":"1125_CR80","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1093\/ehjcvp\/pvad001","volume":"9","author":"G Filippatos","year":"2023","unstructured":"Filippatos, G. et al. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur. Heart J. Cardiovasc. Pharmacother. 9, 183\u2013191 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"1125_CR81","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","volume":"78","author":"G Filippatos","year":"2021","unstructured":"Filippatos, G. et al. Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J. Am. Coll. Cardiol. 78, 142\u2013152 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1125_CR82","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709\u2013717 (1999).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR83","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt, B. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348, 1309\u20131321 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR84","doi-asserted-by":"publisher","first-page":"888","DOI":"10.2337\/dc21-1944","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing, P. et al. Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. Diabetes Care 45, 888\u2013897 (2022).","journal-title":"Diabetes Care"},{"key":"1125_CR85","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR86","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2025.09","volume":"11","author":"SK Patel","year":"2025","unstructured":"Patel, S. K., Teoh, H., Saunthar, A., Yau, T. M. & Verma, S. The emerging role of aldosterone synthase inhibitors in overcoming renin-angiotensin-aldosterone system therapy limitations: a narrative review. Card. Fail. Rev. 11, e20 (2025).","journal-title":"Card. Fail. Rev."},{"key":"1125_CR87","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman, M. W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl. J. Med. 388, 395\u2013405 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR88","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena, M. et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA 334, 409\u2013418 (2025).","journal-title":"JAMA"},{"key":"1125_CR89","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin, L. J. et al. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the Target-HTN randomized clinical trial. JAMA 330, 1140\u20131150 (2023).","journal-title":"JAMA"},{"key":"1125_CR90","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin, L. J. et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N. Engl. J. Med. 392, 1813\u20131823 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR91","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack, J. M. et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N. Engl. J. Med. 393, 1363\u20131374 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR92","doi-asserted-by":"publisher","DOI":"10.1111\/jch.70155","volume":"27","author":"A Dad","year":"2025","unstructured":"Dad, A. et al. Efficacy and safety of lorundrostat in uncontrolled hypertension: a systematic review and meta-analysis. J. Clin. Hypertens. 27, e70155 (2025).","journal-title":"J. Clin. Hypertens."},{"key":"1125_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/biom15101439","volume":"15","author":"E M\u0142ynarska","year":"2025","unstructured":"M\u0142ynarska, E. et al. Baxdrostat: a next-generation aldosterone synthase inhibitor offering new hope in resistant hypertension. Biomolecules 15, 1439 (2025).","journal-title":"Biomolecules"},{"key":"1125_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2023.106409","volume":"235","author":"E Pignatti","year":"2023","unstructured":"Pignatti, E. et al. Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate. J. Steroid Biochem. Mol. Biol. 235, 106409 (2023).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1125_CR95","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2337\/db16-1354","volume":"66","author":"Y-Y Zhang","year":"2017","unstructured":"Zhang, Y.-Y. et al. Deletion of macrophage mineralocorticoid receptor protects hepatic steatosis and insulin resistance through ER\u03b1\/HGF\/Met pathway. Diabetes 66, 1535\u20131547 (2017).","journal-title":"Diabetes"},{"key":"1125_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-172","volume":"12","author":"E Ram\u00edrez","year":"2013","unstructured":"Ram\u00edrez, E. et al. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovasc. Diabetol. 12, 172 (2013).","journal-title":"Cardiovasc. Diabetol."},{"key":"1125_CR97","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/jhh.2012.29","volume":"27","author":"C de Haro Moraes","year":"2013","unstructured":"de Haro Moraes, C. et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J. Hum. Hypertens. 27, 225\u2013230 (2013).","journal-title":"J. Hum. Hypertens."},{"key":"1125_CR98","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","volume":"45","author":"V Marzolla","year":"2022","unstructured":"Marzolla, V. et al. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J. Endocrinol. Invest. 45, 215\u2013220 (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"1125_CR99","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","volume":"66","author":"R Urbanet","year":"2015","unstructured":"Urbanet, R. et al. Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension 66, 149\u2013157 (2015).","journal-title":"Hypertension"},{"key":"1125_CR100","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqac145","volume":"163","author":"JL Hulse","year":"2022","unstructured":"Hulse, J. L. et al. Mineralocorticoid receptors mediate diet-induced lipid infiltration of skeletal muscle and insulin resistance. Endocrinology 163, bqac145 (2022).","journal-title":"Endocrinology"},{"key":"1125_CR101","doi-asserted-by":"publisher","first-page":"H1126","DOI":"10.1152\/ajpheart.00898.2014","volume":"308","author":"B Bostick","year":"2015","unstructured":"Bostick, B. et al. Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am. J. Physiol. Heart Circ. Physiol. 308, H1126\u2013H1135 (2015).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1125_CR102","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.05674","volume":"66","author":"VG DeMarco","year":"2015","unstructured":"DeMarco, V. G. et al. Low-dose mineralocorticoid receptor blockade prevents Western diet-induced arterial stiffening in female mice. Hypertension 66, 99\u2013107 (2015).","journal-title":"Hypertension"},{"key":"1125_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00223","volume":"11","author":"A Vecchiola","year":"2020","unstructured":"Vecchiola, A. et al. Eplerenone implantation improved adipose dysfunction averting RAAS activation and cell division. Front. Endocrinol. 11, 223 (2020).","journal-title":"Front. Endocrinol."},{"key":"1125_CR104","doi-asserted-by":"publisher","first-page":"E1415","DOI":"10.1152\/ajpendo.00419.2013","volume":"305","author":"T Wada","year":"2013","unstructured":"Wada, T. et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am. J. Physiol. Endocrinol. Metab. 305, E1415\u2013E1425 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1125_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01991-2","volume":"22","author":"MM Mohib","year":"2024","unstructured":"Mohib, M. M. et al. Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism. Cell Commun. Signal. 22, 614 (2024).","journal-title":"Cell Commun. Signal."},{"key":"1125_CR106","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1665-2681(19)30935-4","volume":"11","author":"A Taye","year":"2012","unstructured":"Taye, A. & Abdel-Raheem, I. T. Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats. Ann. Hepatol. 11, 384\u2013391 (2012).","journal-title":"Ann. Hepatol."},{"key":"1125_CR107","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1161\/HYPERTENSIONAHA.115.05148","volume":"66","author":"CE Gomez-Sanchez","year":"2015","unstructured":"Gomez-Sanchez, C. E. What is the role of the adipocyte mineralocorticoid receptor in the metabolic syndrome? Hypertension 66, 17\u201319 (2015).","journal-title":"Hypertension"},{"key":"1125_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tem.2019.11.006","volume":"31","author":"A Feraco","year":"2020","unstructured":"Feraco, A., Marzolla, V., Scuteri, A., Armani, A. & Caprio, M. Mineralocorticoid receptors in metabolic syndrome: from physiology to disease. Trends Endocrinol. Metab. 31, 205\u2013217 (2020).","journal-title":"Trends Endocrinol. Metab."},{"key":"1125_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.859812","volume":"13","author":"R Palacios-Ramirez","year":"2022","unstructured":"Palacios-Ramirez, R. et al. Mineralocorticoid receptor antagonism prevents the synergistic effect of metabolic challenge and chronic kidney disease on renal fibrosis and inflammation in mice. Front. Physiol. 13, 859812 (2022).","journal-title":"Front. Physiol."},{"key":"1125_CR110","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1111\/dom.70587","volume":"28","author":"AK Mottl","year":"2026","unstructured":"Mottl, A. K., Khunti, K. & Mathieu, C. Mineralocorticoid receptor antagonists: efficacy and safety in chronic kidney disease. Diabetes Obes. Metab. 28, 3568\u20133581 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"1125_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25169088","volume":"25","author":"L Varda","year":"2024","unstructured":"Varda, L., Ekart, R., Lainscak, M., Maver, U. & Bevc, S. Clinical properties and non-clinical testing of mineralocorticoid receptor antagonists in in vitro cell models. Int. J. Mol. Sci. 25, 9088 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR112","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002043RR","volume":"35","author":"F Le Billan","year":"2021","unstructured":"Le Billan, F. et al. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J. 35, e21314 (2021).","journal-title":"FASEB J."},{"key":"1125_CR113","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71, 599\u2013608 (2018).","journal-title":"Hypertension"},{"key":"1125_CR114","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41440-024-01733-4","volume":"47","author":"S Ikeda","year":"2024","unstructured":"Ikeda, S. et al. Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertens. Res. 47, 2133\u20132143 (2024).","journal-title":"Hypertens. Res."},{"key":"1125_CR115","doi-asserted-by":"publisher","DOI":"10.1172\/JCI157165","volume":"134","author":"A Abedini","year":"2024","unstructured":"Abedini, A. et al. Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists. J. Clin. Invest. 134, e157165 (2024).","journal-title":"J. Clin. Invest."},{"key":"1125_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez, R. et al. Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front. Pharmacol. 9, 1131 (2018).","journal-title":"Front. Pharmacol."},{"key":"1125_CR117","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.14448","volume":"8","author":"CJ Leader","year":"2020","unstructured":"Leader, C. J., Kelly, D. J., Sammut, I. A., Wilkins, G. T. & Walker, R. J. Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat. Physiol. Rep. 8, e14448 (2020).","journal-title":"Physiol. Rep."},{"key":"1125_CR118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23126680","volume":"23","author":"T Nakamura","year":"2022","unstructured":"Nakamura, T. et al. Biglycan is a novel mineralocorticoid receptor target involved in aldosterone\/salt-induced glomerular injury. Int. J. Mol. Sci. 23, 6680 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109396","volume":"113","author":"Y Han","year":"2022","unstructured":"Han, Y. et al. Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR\/CTGF pathway. Int. Immunopharmacol. 113, 109396 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"1125_CR120","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1283729","volume":"2022","author":"Y Chang","year":"2022","unstructured":"Chang, Y. et al. Eplerenone prevents cardiac fibrosis by inhibiting angiogenesis in unilateral urinary obstruction rats. J. Renin Angiotensin Aldosterone Syst. 2022, 1283729 (2022).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"1125_CR121","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","volume":"6","author":"PI Georgianos","year":"2021","unstructured":"Georgianos, P. I. & Agarwal, R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int. Rep. 6, 2281\u20132291 (2021).","journal-title":"Kidney Int. Rep."},{"key":"1125_CR122","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2021.10.023","volume":"582","author":"F Hammer","year":"2021","unstructured":"Hammer, F. et al. Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochem. Biophys. Res. Commun. 582, 28\u201334 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1125_CR123","doi-asserted-by":"publisher","first-page":"F967","DOI":"10.1152\/ajprenal.00669.2014","volume":"309","author":"N Tatsumoto","year":"2015","unstructured":"Tatsumoto, N. et al. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification. Am. J. Physiol. Ren. Physiol. 309, F967\u2013F979 (2015).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1125_CR124","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","volume":"179","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal, J., Jaisser, F. & Anders, H.-J. The mineralocorticoid receptor in chronic kidney disease. Br. J. Pharmacol. 179, 3152\u20133164 (2022).","journal-title":"Br. J. Pharmacol."},{"key":"1125_CR125","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1042\/CS20211075","volume":"136","author":"Y Wu","year":"2022","unstructured":"Wu, Y. et al. AIqM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress. Clin. Sci.136, 103\u2013120 (2022).","journal-title":"Clin. Sci."},{"key":"1125_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102941","volume":"19","author":"R Koyama","year":"2018","unstructured":"Koyama, R. et al. MicroRNA-204 is necessary for aldosterone-stimulated T-type calcium channel expression in cardiomyocytes. Int. J. Mol. Sci. 19, 2941 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR127","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1161\/CIRCRESAHA.117.312451","volume":"122","author":"TR Mesquita","year":"2018","unstructured":"Mesquita, T. R. et al. Specific activation of the alternative cardiac promoter of Cacna1c by the mineralocorticoid receptor. Circ. Res. 122, e49\u2013e61 (2018).","journal-title":"Circ. Res."},{"key":"1125_CR128","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1210\/en.2008-1727","volume":"150","author":"A Maturana","year":"2009","unstructured":"Maturana, A., Lenglet, S., Python, M., Kuroda, S. & Rossier, M. F. Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes. Endocrinology 150, 3726\u20133734 (2009).","journal-title":"Endocrinology"},{"key":"1125_CR129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1161\/HYPERTENSIONAHA.118.12162","volume":"73","author":"D Fraccarollo","year":"2019","unstructured":"Fraccarollo, D. et al. Macrophage mineralocorticoid receptor is a pleiotropic modulator of myocardial infarct healing. Hypertension 73, 102\u2013111 (2019).","journal-title":"Hypertension"},{"key":"1125_CR130","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","volume":"67","author":"A Gueret","year":"2016","unstructured":"Gueret, A. et al. Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction. Hypertension 67, 717\u2013723 (2016).","journal-title":"Hypertension"},{"key":"1125_CR131","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007279","volume":"14","author":"SK Kim","year":"2021","unstructured":"Kim, S. K. et al. Mineralocorticoid receptor in smooth muscle contributes to pressure overload-induced heart failure. Circ. Heart Fail. 14, e007279 (2021).","journal-title":"Circ. Heart Fail."},{"key":"1125_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155372","volume":"21","author":"J Ibarrola","year":"2020","unstructured":"Ibarrola, J. et al. Beneficial effects of mineralocorticoid receptor antagonism on myocardial fibrosis in an experimental model of the myxomatous degeneration of the mitral valve. Int. J. Mol. Sci. 21, 5372 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR133","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1161\/CIRCRESAHA.119.316427","volume":"127","author":"J Ibarrola","year":"2020","unstructured":"Ibarrola, J. et al. A new role for the aldosterone\/mineralocorticoid receptor pathway in the development of mitral valve prolapse. Circ. Res. 127, e80\u2013e93 (2020).","journal-title":"Circ. Res."},{"key":"1125_CR134","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.cjco.2024.06.002","volume":"6","author":"E Le Nezet","year":"2024","unstructured":"Le Nezet, E., Marqueze-Pouey, C., Guisle, I. & Clavel, M.-A. Molecular features of calcific aortic stenosis in female and male patients. CJC Open 6, 1125\u20131137 (2024).","journal-title":"CJC Open"},{"key":"1125_CR135","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/HYPERTENSIONAHA.122.19526","volume":"79","author":"L Matilla","year":"2022","unstructured":"Matilla, L. et al. Sex-related signaling of aldosterone\/mineralocorticoid receptor pathway in calcific aortic stenosis. Hypertension 79, 1724\u20131737 (2022).","journal-title":"Hypertension"},{"key":"1125_CR136","doi-asserted-by":"publisher","first-page":"H639","DOI":"10.1152\/ajpheart.00763.2024","volume":"328","author":"M Go\u00f1i-Ol\u00f3riz","year":"2025","unstructured":"Go\u00f1i-Ol\u00f3riz, M. et al. Chemerin is a new sex-specific target in aortic stenosis concomitant with diabetes regulated by the aldosterone\/mineralocorticoid receptor axis. Am. J. Physiol. Heart Circ. Physiol. 328, H639\u2013H647 (2025).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1125_CR137","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.125.047941","volume":"15","author":"T S\u00e1nchez-Bayuela","year":"2026","unstructured":"S\u00e1nchez-Bayuela, T. et al. Chemerin activation of toll-like receptor 4 drives mineralocorticoid receptor-mediated aortic valve remodeling in chronic kidney disease. J. Am. Heart Assoc. 15, e047941 (2026).","journal-title":"J. Am. Heart Assoc."},{"key":"1125_CR138","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","volume":"63","author":"C.A Amador","year":"2014","unstructured":"Amador, C.A. et al. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertens. 63, 797-803 (2014).","journal-title":"Hypertens."},{"key":"1125_CR139","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","volume":"52","author":"L Michea","year":"2008","unstructured":"Michea, L. et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats. Hypertens. 52, 295-300 (2008).","journal-title":"Hypertens."},{"key":"1125_CR140","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3892\/mmr.2020.11260","volume":"22","author":"D Hu","year":"2020","unstructured":"Hu, D. et al. Age-related changes in mineralocorticoid receptors in rat hearts. Mol. Med. Rep. 22, 1859\u20131867 (2020).","journal-title":"Mol. Med. Rep."},{"key":"1125_CR141","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/HYPERTENSIONAHA.118.11604","volume":"73","author":"NJ Brown","year":"2019","unstructured":"Brown, N. J. Mineralocorticoid receptor activation and atrial fibrosis. Hypertension 73, 294\u2013295 (2019).","journal-title":"Hypertension"},{"key":"1125_CR142","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/hr.2010.277","volume":"34","author":"S Kimura","year":"2011","unstructured":"Kimura, S. et al. Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats. Hypertens. Res. 34, 584\u2013591 (2011).","journal-title":"Hypertens. Res."},{"key":"1125_CR143","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.116.07911","volume":"68","author":"JA Victorio","year":"2016","unstructured":"Victorio, J. A. et al. Spironolactone prevents endothelial nitric oxide synthase uncoupling and vascular dysfunction induced by \u03b2-adrenergic overstimulation: role of perivascular adipose tissue. Hypertension 68, 726\u2013735 (2016).","journal-title":"Hypertension"},{"key":"1125_CR144","doi-asserted-by":"publisher","first-page":"1118516","DOI":"10.3389\/fcvm.2023.1118516","volume":"10","author":"A Mamazhakypov","year":"2023","unstructured":"Mamazhakypov, A. & Lother, A. Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: insights from basic research. Front. Cardiovasc. Med. 10, 1118516 (2023).","journal-title":"Front. Cardiovasc. Med."},{"key":"1125_CR145","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2018.10.002","volume":"125","author":"M Huang","year":"2018","unstructured":"Huang, M. et al. 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor attenuates high-fat diet induced cardiomyopathy. J. Mol. Cell. Cardiol. 125, 106\u2013116 (2018).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1125_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2025.104191","volume":"35","author":"M Wang","year":"2025","unstructured":"Wang, M. et al. Mineralocorticoid receptor regulates vascular damage by inducing autophagy in mice with obesity and hypertension. Nutr. Metab. Cardiovasc. Dis. 35, 104191 (2025).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1125_CR147","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1152\/ajpregu.00274.2021","volume":"324","author":"A Aroor","year":"2023","unstructured":"Aroor, A. et al. Endothelial cell-specific mineralocorticoid receptor activation promotes diastolic dysfunction in diet-induced obese male mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 324, R90\u2013R101 (2023).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1125_CR148","doi-asserted-by":"publisher","DOI":"10.1111\/dme.70154","volume":"43","author":"AK Banah","year":"2025","unstructured":"Banah, A. K. et al. Eplerenone improves kidney function and cardiac performance in obese male mice. Diabet. Med. 43, e70154 (2025).","journal-title":"Diabet. Med."},{"key":"1125_CR149","doi-asserted-by":"publisher","first-page":"3244","DOI":"10.1038\/s41440-025-02401-x","volume":"48","author":"R Mitsuno","year":"2025","unstructured":"Mitsuno, R. et al. Effects of perirenal fat accumulation on cardiometabolic and renal functions and mineralocorticoid receptor activation in primary aldosteronism. Hypertens. Res. 48, 3244\u20133256 (2025).","journal-title":"Hypertens. Res."},{"key":"1125_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032536","volume":"24","author":"I Lima-Posada","year":"2023","unstructured":"Lima-Posada, I. et al. Benefits of the non-steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failure with preserved ejection fraction. Int. J. Mol. Sci. 24, 2536 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102946","volume":"68","author":"L Yao","year":"2023","unstructured":"Yao, L. et al. Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K\/Akt\/eNOS signaling pathway in diabetic tubulopathy. Redox Biol. 68, 102946 (2023).","journal-title":"Redox Biol."},{"key":"1125_CR152","doi-asserted-by":"publisher","first-page":"F724","DOI":"10.1152\/ajprenal.00136.2025","volume":"329","author":"K Myakala","year":"2025","unstructured":"Myakala, K. et al. The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation. Am. J. Physiol. Ren. Physiol. 329, F724\u2013F743 (2025).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1125_CR153","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01064-3","volume":"15","author":"T Jin","year":"2023","unstructured":"Jin, T., Fu, X., Liu, M. & An, F. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol. Metab. Syndr. 15, 87 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"1125_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1364827","volume":"15","author":"L Xie","year":"2024","unstructured":"Xie, L. et al. Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy. Front. Pharmacol. 15, 1364827 (2024).","journal-title":"Front. Pharmacol."},{"key":"1125_CR155","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezad405","volume":"64","author":"H Yamashita","year":"2023","unstructured":"Yamashita, H., Fujii, M., Bessho, R. & Ishii, Y. Effect of esaxerenone on ischaemia and reperfusion injury in rat hearts. Eur. J. Cardiothorac. Surg. 64, ezad405 (2023).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1125_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123319","volume":"11","author":"Z Li","year":"2023","unstructured":"Li, Z. et al. Esaxerenone protects against diabetic cardiomyopathy via inhibition of the chemokine and PI3K-Akt signaling pathway. Biomedicines 11, 3319 (2023).","journal-title":"Biomedicines"},{"key":"1125_CR157","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95324-z","volume":"15","author":"H Iwamoto","year":"2025","unstructured":"Iwamoto, H. et al. Blocking mineralocorticoid signaling with esaxerenone reduces atherosclerosis in hyperglycemic ApoE KO mice without affecting blood pressure and glycolipid metabolism. Sci. Rep. 15, 10887 (2025).","journal-title":"Sci. Rep."},{"key":"1125_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21087-5","volume":"8","author":"A Nguyen Dinh Cat","year":"2018","unstructured":"Nguyen Dinh Cat, A. et al. Vascular dysfunction in obese diabetic db\/db mice involves the interplay between aldosterone\/mineralocorticoid receptor and Rho kinase signaling. Sci. Rep. 8, 2952 (2018).","journal-title":"Sci. Rep."},{"key":"1125_CR159","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20160086","volume":"36","author":"D Li","year":"2016","unstructured":"Li, D. et al. Spironolactone promotes autophagy via inhibiting PI3K\/AKT\/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress. Biosci. Rep. 36, e00355 (2016).","journal-title":"Biosci. Rep."},{"key":"1125_CR160","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1113\/JP277002","volume":"597","author":"S Koszegi","year":"2019","unstructured":"Koszegi, S. et al. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition. J. Physiol. 597, 193\u2013209 (2019).","journal-title":"J. Physiol."},{"key":"1125_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1534-4","volume":"20","author":"CC Wang","year":"2019","unstructured":"Wang, C. C. et al. Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE\/RAGE axis in a chronic renal failure rat model. BMC Nephrol. 20, 351 (2019).","journal-title":"BMC Nephrol."},{"key":"1125_CR162","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154164","volume":"8","author":"M Crompton","year":"2023","unstructured":"Crompton, M. et al. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight 8, e154164 (2023).","journal-title":"JCI Insight"},{"key":"1125_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cells14050337","volume":"14","author":"Z-H Li","year":"2025","unstructured":"Li, Z.-H. et al. Finerenone alleviates over-activation of complemlement C5a-C5aR1 axis of macrophages by regulating G protein subunit alpha i2 to improve diabetic nephropathy. Cells 14, 337 (2025).","journal-title":"Cells"},{"key":"1125_CR164","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115661","volume":"168","author":"M Sanz-G\u00f3mez","year":"2023","unstructured":"Sanz-G\u00f3mez, M. et al. Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors. Biomed. Pharmacother. 168, 115661 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"1125_CR165","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00210-023-02665-5","volume":"397","author":"C-J Wu","year":"2024","unstructured":"Wu, C.-J., Li, Y.-H., Wu, F.-Z. & Chen, H.-H. Eplerenone improves hyperglycemia and sympathetic excitation in chronic renocardiac syndrome in rats. Naunyn. Schmiedebergs Arch. Pharmacol. 397, 1081\u20131092 (2024).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"1125_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115381","volume":"411","author":"KS Olaniyi","year":"2021","unstructured":"Olaniyi, K. S. et al. Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS. Toxicol. Appl. Pharmacol. 411, 115381 (2021).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1125_CR167","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40200-022-01097-x","volume":"21","author":"EG Uhunmwangho","year":"2022","unstructured":"Uhunmwangho, E. G. et al. Mineralocorticoid receptor blockade attenuates hyperandrogenic metabolic dysregulation in letrozole-induced PCOS rat model. J. Diabetes Metab. Disord. 21, 1539\u20131547 (2022).","journal-title":"J. Diabetes Metab. Disord."},{"key":"1125_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1125693","volume":"14","author":"R Lv","year":"2023","unstructured":"Lv, R. et al. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Front. Endocrinol. 14, 1125693 (2023).","journal-title":"Front. Endocrinol."},{"key":"1125_CR169","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1248\/bpb.b25-00009","volume":"48","author":"K Taguchi","year":"2025","unstructured":"Taguchi, K., Furukawa, T., Matsumoto, T. & Kobayashi, T. Esaxerenone improves vascular endothelial dysfunction by reducing serum and glucocorticoid-regulated kinase 1 activity and enhancing the Akt pathway in type 2 diabetic mice. Biol. Pharm. Bull. 48, 422\u2013431 (2025).","journal-title":"Biol. Pharm. Bull."},{"key":"1125_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78321-6","volume":"14","author":"K Taguchi","year":"2024","unstructured":"Taguchi, K., Kondo, H., Matsumoto, T. & Kobayashi, T. Effect of esaxerenone on the onset of aortic endothelial dysfunction and circulating microparticles in type 1 diabetic male mice. Sci. Rep. 14, 26266 (2024).","journal-title":"Sci. Rep."},{"key":"1125_CR171","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/FJC.0000000000001316","volume":"80","author":"H Yamamoto","year":"2022","unstructured":"Yamamoto, H., Yoshida, N. & Kihara, S. Esaxerenone blocks vascular endothelial inflammation through SGK1. J. Cardiovasc. Pharmacol. 80, 583\u2013591 (2022).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1125_CR172","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00424-012-1145-4","volume":"464","author":"A Todkar","year":"2012","unstructured":"Todkar, A. et al. Aldosterone deficiency adversely affects pregnancy outcome in mice. Pflugers Arch. 464, 331\u2013343 (2012).","journal-title":"Pflugers Arch."},{"key":"1125_CR173","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/j.2040-4603.2021.tb00148.x","volume":"11","author":"BA Bakrania","year":"2020","unstructured":"Bakrania, B. A. et al. Preeclampsia: linking placental ischemia with maternal endothelial and vascular dysfunction. Compr. Physiol. 11, 1315\u20131349 (2020).","journal-title":"Compr. Physiol."},{"key":"1125_CR174","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3109\/14767058.2014.951627","volume":"28","author":"MN Uddin","year":"2015","unstructured":"Uddin, M. N. et al. Suppression of aldosterone and progesterone in preeclampsia. J. Matern. Fetal Neonatal Med. 28, 1296\u20131301 (2015).","journal-title":"J. Matern. Fetal Neonatal Med."},{"key":"1125_CR175","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.125.321675","volume":"46","author":"J Lutshumba","year":"2026","unstructured":"Lutshumba, J. et al. Renin-angiotensin-aldosterone system in preeclampsia: pathophysiological insights and links to vascular dementia. Arterioscler. Thromb. Vasc. Biol. 46, e321675 (2026).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1125_CR176","unstructured":"The Human Protein Atlas. CYP11B2: pancreas. The Human Protein Atlas https:\/\/www.proteinatlas.org\/ENSG00000179142-CYP11B2\/tissue\/pancreas (accessed 2026)."},{"key":"1125_CR177","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","volume":"54","author":"JM Luther","year":"2011","unstructured":"Luther, J. M. et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54, 2152\u20132163 (2011).","journal-title":"Diabetologia"},{"key":"1125_CR178","doi-asserted-by":"publisher","DOI":"10.1038\/srep13215","volume":"5","author":"F Chen","year":"2015","unstructured":"Chen, F. et al. Aldosterone induces clonal \u03b2-cell failure through glucocorticoid receptor. Sci. Rep. 5, 13215 (2015).","journal-title":"Sci. Rep."},{"key":"1125_CR179","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/HYPERTENSIONAHA.111.180521","volume":"58","author":"E Kumagai","year":"2011","unstructured":"Kumagai, E. et al. Plasma aldosterone levels and development of insulin resistance: prospective study in a general population. Hypertension 58, 1043\u20131048 (2011).","journal-title":"Hypertension"},{"key":"1125_CR180","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.pcad.2009.12.004","volume":"52","author":"A Whaley-Connell","year":"2010","unstructured":"Whaley-Connell, A., Johnson, M. S. & Sowers, J. R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 52, 401\u2013409 (2010).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"1125_CR181","first-page":"149","volume":"148","author":"G Fujisawa","year":"2006","unstructured":"Fujisawa, G., Muto, S., Okada, K., Kusano, E. & Ishibashi, S. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl. Res. J. Lab. Clin. Med. 148, 149\u2013156 (2006).","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"1125_CR182","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","volume":"30","author":"G Colussi","year":"2007","unstructured":"Colussi, G. et al. Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30, 2349\u20132354 (2007).","journal-title":"Diabetes Care"},{"key":"1125_CR183","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1210\/jc.2016-1002","volume":"101","author":"JJ Joseph","year":"2016","unstructured":"Joseph, J. J. et al. Aldosterone, renin, and diabetes mellitus in African Americans: the Jackson Heart Study. J. Clin. Endocrinol. Metab. 101, 1770\u20131778 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1125_CR184","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s40265-025-02229-2","volume":"85","author":"AFG Cicero","year":"2025","unstructured":"Cicero, A. F. G. et al. Aldosterone synthase inhibitors for resistant hypertension: pharmacological insights \u2014 a systematic review. Drugs 85, 1429\u20131453 (2025).","journal-title":"Drugs"},{"key":"1125_CR185","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1161\/HYPERTENSIONAHA.124.23962","volume":"82","author":"L Marzano","year":"2025","unstructured":"Marzano, L., Merlo, M., Martinelli, N., Pizzolo, F. & Friso, S. Efficacy and safety of aldosterone synthase inhibitors for hypertension: a meta-analysis of randomized controlled trials and systematic review. Hypertension 82, e47\u2013e56 (2025).","journal-title":"Hypertension"},{"key":"1125_CR186","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2008.03498.x","volume":"71","author":"G Lastra-Lastra","year":"2009","unstructured":"Lastra-Lastra, G., Sowers, J. R., Restrepo-Erazo, K., Manrique-Acevedo, C. & Lastra-Gonz\u00e1lez, G. Role of aldosterone and angiotensin II in insulin resistance: an update. Clin. Endocrinol. 71, 1\u20136 (2009).","journal-title":"Clin. Endocrinol."},{"key":"1125_CR187","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99015","volume":"3","author":"W-H Liao","year":"2018","unstructured":"Liao, W.-H. et al. Aldosterone deficiency in mice burdens respiration and accentuates diet-induced hyperinsulinemia and obesity. JCI Insight 3, e99015 (2018).","journal-title":"JCI Insight"},{"key":"1125_CR188","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1055\/s-0043-101821","volume":"49","author":"A Hofmann","year":"2017","unstructured":"Hofmann, A. et al. The aldosterone synthase inhibitor FAD286 is suitable for lowering aldosterone levels in ZDF rats but not in db\/db mice. Horm. Metab. Res. 49, 466\u2013471 (2017).","journal-title":"Horm. Metab. Res."},{"key":"1125_CR189","unstructured":"The Human Protein Atlas. CYP11B2: kidney. The Human Protein Atlas https:\/\/www.proteinatlas.org\/ENSG00000179142-CYP11B2\/tissue\/kidney (accessed 2026)."},{"key":"1125_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/biology13121084","volume":"13","author":"H Gu","year":"2024","unstructured":"Gu, H. et al. The effects of aldosterone on hypertension-associated kidney injury in a Tg-hAS mouse model. Biology 13, 1084 (2024).","journal-title":"Biology"},{"key":"1125_CR191","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00461-9","volume":"7","author":"H Gu","year":"2017","unstructured":"Gu, H. et al. Salt-dependent blood pressure in human aldosterone synthase-transgenic mice. Sci. Rep. 7, 492 (2017).","journal-title":"Sci. Rep."},{"key":"1125_CR192","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","volume":"111","author":"A Fiebeler","year":"2005","unstructured":"Fiebeler, A. et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 111, 3087\u20133094 (2005).","journal-title":"Circulation"},{"key":"1125_CR193","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ki.2009.9","volume":"75","author":"WB Lea","year":"2009","unstructured":"Lea, W. B. et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 75, 936\u2013944 (2009).","journal-title":"Kidney Int."},{"key":"1125_CR194","doi-asserted-by":"publisher","first-page":"F1402","DOI":"10.1152\/ajprenal.00691.2010","volume":"300","author":"H Kawarazaki","year":"2011","unstructured":"Kawarazaki, H. et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am. J. Physiol. Ren. Physiol. 300, F1402\u2013F1409 (2011).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"1125_CR195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103649","volume":"392","author":"SM Weldon","year":"2025","unstructured":"Weldon, S. M. et al. Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: contrasting effects of once versus twice daily dosing. J. Pharmacol. Exp. Ther. 392, 103649 (2025).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1125_CR196","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1124\/jpet.116.236463","volume":"359","author":"SM Weldon","year":"2016","unstructured":"Weldon, S. M. et al. Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates. J. Pharmacol. Exp. Ther. 359, 142\u2013150 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1125_CR197","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-OR09-6","volume":"3","author":"S Sparks","year":"2019","unstructured":"Sparks, S., Garvey, E., Hoekstra, W., Schotzinger, R. & Becherer, J. D. Selective and durable suppression of aldosterone production in non-human primates by a novel aldosterone synthase inhibitor [abstract]. J. Endocr. Soc. 3, OR09-6 (2019).","journal-title":"J. Endocr. Soc."},{"key":"1125_CR198","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1042\/cs1020381","volume":"102","author":"M Satoh","year":"2002","unstructured":"Satoh, M. et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. 102, 381\u2013386 (2002).","journal-title":"Clin. Sci."},{"key":"1125_CR199","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01882-2","volume":"7","author":"I Alesutan","year":"2017","unstructured":"Alesutan, I. et al. Involvement of vascular aldosterone synthase in phosphate-induced osteogenic transformation of vascular smooth muscle cells. Sci. Rep. 7, 2059 (2017).","journal-title":"Sci. Rep."},{"key":"1125_CR200","first-page":"2797","volume":"81","author":"Y Takeda","year":"1996","unstructured":"Takeda, Y. et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J. Clin. Endocrinol. Metab. 81, 2797\u20132800 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1125_CR201","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1161\/01.HYP.36.4.495","volume":"36","author":"Y Takeda","year":"2000","unstructured":"Takeda, Y., Yoneda, T., Demura, M., Miyamori, I. & Mabuchi, H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36, 495\u2013500 (2000).","journal-title":"Hypertension"},{"key":"1125_CR202","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1590\/1414-431x20143474","volume":"47","author":"XQ Zhu","year":"2014","unstructured":"Zhu, X. Q., Hong, H. S., Lin, X. H., Chen, L. L. & Li, Y. H. Changes in cardiac aldosterone and its synthase in rats with chronic heart failure: an intervention study of long-term treatment with recombinant human brain natriuretic peptide. Braz. J. Med. Biol. Res. 47, 646\u2013654 (2014).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"1125_CR203","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1210\/jcem.87.8.8731","volume":"87","author":"M Yoshimura","year":"2002","unstructured":"Yoshimura, M. et al. Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J. Clin. Endocrinol. Metab. 87, 3936\u20133940 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1125_CR204","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315061","volume":"23","author":"Y-S Zhai","year":"2022","unstructured":"Zhai, Y.-S., Li, J., Peng, L., Lu, G. & Gao, X. Phosphorylation of CaMK and CREB-mediated cardiac aldosterone synthesis induced by arginine vasopressin in rats with myocardial infarction. Int. J. Mol. Sci. 23, 15061 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR205","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s11033-019-05222-7","volume":"47","author":"W-W Zhang","year":"2020","unstructured":"Zhang, W.-W. et al. Steroidogenic acute regulatory protein\/aldosterone synthase mediates angiotensin II-induced cardiac fibrosis and hypertrophy. Mol. Biol. Rep. 47, 1207\u20131222 (2020).","journal-title":"Mol. Biol. Rep."},{"key":"1125_CR206","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/161396","volume":"2013","author":"M Fujisaki","year":"2013","unstructured":"Fujisaki, M., Nagoshi, T., Nishikawa, T., Date, T. & Yoshimura, M. Rapid induction of aldosterone synthesis in cultured neonatal rat cardiomyocytes under high glucose conditions. Biomed. Res. Int. 2013, 161396 (2013).","journal-title":"Biomed. Res. Int."},{"key":"1125_CR207","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier, A. et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110, 1819\u20131825 (2004).","journal-title":"Circulation"},{"key":"1125_CR208","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.107.722009","volume":"116","author":"M-L Ambroisine","year":"2007","unstructured":"Ambroisine, M.-L. et al. Aldosterone-induced coronary dysfunction in transgenic mice involves the calcium-activated potassium (BKCa) channels of vascular smooth muscle cells. Circulation 116, 2435\u20132443 (2007).","journal-title":"Circulation"},{"key":"1125_CR209","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1096\/fj.14-259606","volume":"30","author":"P Jeggle","year":"2016","unstructured":"Jeggle, P., Hofschr\u00f6er, V., Maase, M., Bertog, M. & Kusche-Vihrog, K. Aldosterone synthase knockout mouse as a model for sodium-induced endothelial sodium channel up-regulation in vascular endothelium. FASEB J. 30, 45\u201353 (2016).","journal-title":"FASEB J."},{"key":"1125_CR210","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/ki.2012.170","volume":"82","author":"JM Luther","year":"2012","unstructured":"Luther, J. M. et al. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney Int. 82, 643\u2013651 (2012).","journal-title":"Kidney Int."},{"key":"1125_CR211","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1161\/HYPERTENSIONAHA.107.098897","volume":"51","author":"N Makhanova","year":"2008","unstructured":"Makhanova, N., Hagaman, J., Kim, H.-S. & Smithies, O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension 51, 134\u2013140 (2008).","journal-title":"Hypertension"},{"key":"1125_CR212","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejphar.2016.11.049","volume":"795","author":"S Furuzono","year":"2017","unstructured":"Furuzono, S. et al. A novel aldosterone synthase inhibitor ameliorates mortality in pressure-overload mice with heart failure. Eur. J. Pharmacol. 795, 58\u201365 (2017).","journal-title":"Eur. J. Pharmacol."},{"key":"1125_CR213","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","volume":"29","author":"P Mulder","year":"2008","unstructured":"Mulder, P. et al. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur. Heart J. 29, 2171\u20132179 (2008).","journal-title":"Eur. Heart J."},{"key":"1125_CR214","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/cvr\/cvn222","volume":"81","author":"BS Huang","year":"2009","unstructured":"Huang, B. S. et al. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodelling in rats after myocardial infarction. Cardiovasc. Res. 81, 574\u2013581 (2009).","journal-title":"Cardiovasc. Res."},{"key":"1125_CR215","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0340-9","volume":"12","author":"J M\u00e9nard","year":"2014","unstructured":"M\u00e9nard, J. et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. J. Transl. Med. 12, 340 (2014).","journal-title":"J. Transl. Med."},{"key":"1125_CR216","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00125-012-2814-8","volume":"56","author":"P Luo","year":"2013","unstructured":"Luo, P. et al. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 56, 901\u2013910 (2013).","journal-title":"Diabetologia"},{"key":"1125_CR217","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1210\/en.2016-1358","volume":"157","author":"A Hofmann","year":"2016","unstructured":"Hofmann, A. et al. Aldosterone synthase inhibition improves glucose tolerance in Zucker Diabetic Fatty (ZDF) rats. Endocrinology 157, 3844\u20133855 (2016).","journal-title":"Endocrinology"},{"key":"1125_CR218","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FJC.0b013e318274d2ef","volume":"61","author":"LC Matavelli","year":"2013","unstructured":"Matavelli, L. C. & Siragy, H. M. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. J. Cardiovasc. Pharmacol. 61, 17\u201322 (2013).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1125_CR219","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez, P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243\u20131248 (2005).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1125_CR220","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone, S. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol.\u00a06, 41\u201350 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1125_CR221","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad, F. et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364, 11\u201321 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR222","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC): Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129\u20132200 (2016).","journal-title":"Eur. Heart J."},{"key":"1125_CR223","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich, P. A. et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145, e895\u2013e1032 (2022).","journal-title":"Circulation"},{"key":"1125_CR224","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt, B. et al. Spironolactone for heart failure with preserved ejection fraction. N. Engl. J. Med. 370, 1383\u20131392 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR225","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131, 34\u201342 (2015).","journal-title":"Circulation"},{"key":"1125_CR226","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMc1612601","volume":"376","author":"S de Denus","year":"2017","unstructured":"de Denus, S. et al. Spironolactone metabolites in TOPCAT - new insights into regional variation. N. Engl. J. Med. 376, 1690\u20131692 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR227","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon, S. D. et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 391, 1475\u20131485 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR228","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2024.10.091","volume":"85","author":"FR Mc Causland","year":"2025","unstructured":"Mc Causland, F. R. et al. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J. Am. Coll. Cardiol. 85, 159\u2013168 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1125_CR229","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","volume":"13","author":"JH Butt","year":"2025","unstructured":"Butt, J. H. et al. Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial. Lancet Diabetes Endocrinol. 13, 107\u2013118 (2025).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1125_CR230","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s10557-025-07822-x","volume":"40","author":"E Habib","year":"2026","unstructured":"Habib, E. et al. Finerenone versus spironolactone for heart failure with preserved ejection fraction. Cardiovasc. Drugs Ther. 40, 1419\u20131422 (2026).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"1125_CR231","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot, G. et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur. Heart J. 35, 2295\u20132302 (2014).","journal-title":"Eur. Heart J."},{"key":"1125_CR232","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","volume":"67","author":"F Beygui","year":"2016","unstructured":"Beygui, F. et al. Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J. Am. Coll. Cardiol. 67, 1917\u20131927 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1125_CR233","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/jamacardio.2017.2198","volume":"2","author":"J Butler","year":"2017","unstructured":"Butler, J. et al. Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol. 2, 950\u2013958 (2017).","journal-title":"JAMA Cardiol."},{"key":"1125_CR234","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams, B. et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386, 2059\u20132068 (2015).","journal-title":"Lancet"},{"key":"1125_CR235","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito, S. et al. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension 75, 51\u201358 (2020).","journal-title":"Hypertension"},{"key":"1125_CR236","doi-asserted-by":"publisher","first-page":"363","DOI":"10.5664\/jcsm.27878","volume":"6","author":"CC Gonzaga","year":"2010","unstructured":"Gonzaga, C. C. et al. Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. J. Clin. Sleep Med. 6, 363\u2013368 (2010).","journal-title":"J. Clin. Sleep Med."},{"key":"1125_CR237","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3109\/10641963.2015.1131290","volume":"38","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea. Clin. Exp. Hypertens. 38, 464\u2013468 (2016).","journal-title":"Clin. Exp. Hypertens."},{"key":"1125_CR238","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR239","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa2512854","volume":"394","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink, H. J. L. et al. Finerenone in type 1 diabetes and chronic kidney disease. N. Engl. J. Med. 394, 947\u2013957 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR240","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito, S. et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin. J. Am. Soc. Nephrol. 15, 1715\u20131727 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1125_CR241","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada, T. et al. Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin. Exp. Nephrol. 25, 120\u2013130 (2021).","journal-title":"Clin. Exp. Nephrol."},{"key":"1125_CR242","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323\u2013334 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR243","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink, H. J. L. et al. Dapagliflozin in patients with chronic kidney disease. N. Engl. J. Med. 383, 1436\u20131446 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR244","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","volume":"18","author":"J Barrera-Chimal","year":"2022","unstructured":"Barrera-Chimal, J., Lima-Posada, I., Bakris, G. L. & Jaisser, F. Mineralocorticoid receptor antagonists in diabetic kidney disease \u2014 mechanistic and therapeutic effects. Nat. Rev. Nephrol. 18, 56\u201370 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"1125_CR245","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon, V. & Verma, S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu. Rev. Physiol. 83, 503\u2013528 (2021).","journal-title":"Annu. Rev. Physiol."},{"key":"1125_CR246","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74934-z","volume":"14","author":"M Souli\u00e9","year":"2024","unstructured":"Souli\u00e9, M. et al. Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease. Sci. Rep. 14, 23955 (2024).","journal-title":"Sci. Rep."},{"key":"1125_CR247","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof, P. et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52, 642\u2013652 (2021).","journal-title":"Am. J. Nephrol."},{"key":"1125_CR248","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","volume":"34","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Finerenone added to RAS\/SGLT2 blockade for CKD in Alport syndrome. results of a randomized controlled trial with Col4a3\u2212\/\u2212 mice. J. Am. Soc. Nephrol. 34, 1513\u20131520 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1125_CR249","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","volume":"33","author":"M Provenzano","year":"2022","unstructured":"Provenzano, M. et al. Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial. J. Am. Soc. Nephrol. 33, 1569\u20131580 (2022).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1125_CR250","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 533\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR251","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.126.27036","volume":"83","author":"R Agarwal","year":"2026","unstructured":"Agarwal, R. et al. Safety and synergy of finerenone and empagliflozin in lowering blood pressure. Hypertension 83, e27036 (2026).","journal-title":"Hypertension"},{"key":"1125_CR252","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/S0140-6736(25)02014-8","volume":"406","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink, H. J. L. et al. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial. Lancet 406, 2449\u20132460 (2025).","journal-title":"Lancet"},{"key":"1125_CR253","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/ndt\/gfaf244","volume":"41","author":"Y Guo","year":"2026","unstructured":"Guo, Y. et al. Efficacy and safety of finerenone with SGLT2i in IgA nephropathy. Nephrol. Dial. Transplant. 41, 1138\u20131146 (2026).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1125_CR254","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad249","volume":"17","author":"FH M\u00e5rup","year":"2024","unstructured":"M\u00e5rup, F. H., Thomsen, M. B. & Birn, H. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial. Clin. Kidney J. 17, sfad249 (2024).","journal-title":"Clin. Kidney J."},{"key":"1125_CR255","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1093\/ndt\/gfaf064","volume":"40","author":"M-H Chuang","year":"2025","unstructured":"Chuang, M.-H. et al. Cardio-kidney outcomes for combined versus monotherapy with finerenone or SGLT2 inhibitors in patients with CKD. Nephrol. Dial. Transplant. 40, 1897\u20131905 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1125_CR256","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262210810","volume":"26","author":"D Delic","year":"2025","unstructured":"Delic, D. et al. Urine extracellular vesicle miRNA changes induced by vicadrostat with\/without empagliflozin in patients with chronic kidney disease. Int. J. Mol. Sci. 26, 10810 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1125_CR257","doi-asserted-by":"publisher","DOI":"10.1530\/JME-25-0047","volume":"75","author":"J Barrera-Chimal","year":"2025","unstructured":"Barrera-Chimal, J., Vaidya, A. & Jaisser, F. Aldosterone synthase inhibition: a novel bullet to fight cardiovascular\u2013kidney\u2013metabolic syndrome. J. Mol. Endocrinol. 75, e250047 (2025).","journal-title":"J. Mol. Endocrinol."},{"key":"1125_CR258","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle, K. R. et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet 403, 379\u2013390 (2024).","journal-title":"Lancet"},{"key":"1125_CR259","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06531824 (2026)."},{"key":"1125_CR260","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","volume":"40","author":"PK Judge","year":"2025","unstructured":"Judge, P. K. et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol. Dial. Transplant. 40, 1175\u20131186 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"1125_CR261","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","volume":"78","author":"G Bakris","year":"2021","unstructured":"Bakris, G. et al. Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension 78, 74\u201381 (2021).","journal-title":"Hypertension"},{"key":"1125_CR262","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04968184 (2025)"},{"key":"1125_CR263","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2604625","volume":"395","author":"HJL Heerspink","year":"2026","unstructured":"Heerspink, H. J. L. et al. Finerenone in persons with chronic kidney disease without diabetes. N. Engl. J. Med. 395, 533\u2013545 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1125_CR264","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jama.2026.9923","volume":"336","author":"BL Neuen","year":"2026","unstructured":"Neuen, B. L. et al. Finerenone in patients with chronic kidney disease due to glomerular diseases: a randomized clinical trial. JAMA 336, 224\u2013235 (2026).","journal-title":"JAMA"},{"key":"1125_CR265","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/dom.13539","volume":"21","author":"M Thuzar","year":"2019","unstructured":"Thuzar, M., Law, W. P., Dimeski, G., Stowasser, M. & Ho, K. K. Y. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study. Diabetes Obes. Metab. 21, 509\u2013516 (2019).","journal-title":"Diabetes Obes. Metab."},{"key":"1125_CR266","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jchf.2021.02.016","volume":"9","author":"NH Brandt-Jacobsen","year":"2021","unstructured":"Brandt-Jacobsen, N. H. et al. Mineralocorticoid receptor antagonist improves cardiac structure in type 2 diabetes: data from the MIRAD trial. JACC Heart Fail. 9, 550\u2013558 (2021).","journal-title":"JACC Heart Fail."},{"key":"1125_CR267","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JGF Cleland","year":"2021","unstructured":"Cleland, J. G. F. et al. The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur. Heart J. 42, 684\u2013696 (2021).","journal-title":"Eur. Heart J."},{"key":"1125_CR268","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0626-9","volume":"18","author":"A Vecchiola","year":"2016","unstructured":"Vecchiola, A., Lagos, C. F., Carvajal, C. A., Baudrand, R. & Fardella, C. E. Aldosterone production and signaling dysregulation in obesity. Curr. Hypertens. Rep. 18, 20 (2016).","journal-title":"Curr. Hypertens. Rep."},{"key":"1125_CR269","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/jamacardio.2026.1365","volume":"11","author":"KB Lo","year":"2026","unstructured":"Lo, K. B. et al. Finerenone across cardiovascular\u2013kidney\u2013metabolic syndrome stages: post hoc analysis of the FIDELITY randomized clinical trials. JAMA Cardiol. 11, 679\u2013684 (2026).","journal-title":"JAMA Cardiol."},{"key":"1125_CR270","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9943848","volume":"21","author":"J Hao","year":"2021","unstructured":"Hao, J. et al. Aldosterone induces the proliferation of renal tubular epithelial cells in vivo but not in vitro. J. Renin Angiotensin Aldosterone Syst. 21, 9943848 (2021).","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"1125_CR271","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal, J. et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int. 93, 1344\u20131355 (2018).","journal-title":"Kidney Int."},{"key":"1125_CR272","doi-asserted-by":"publisher","first-page":"498","DOI":"10.34067\/KID.0000000777","volume":"6","author":"R Liu","year":"2025","unstructured":"Liu, R., Lu, Y. & Juncos, L. A. From receptor to repair: the mechanistic basis of mineralocorticoid receptor antagonism in acute kidney injury and CKD. Kidney360 6, 498\u2013500 (2025).","journal-title":"Kidney360"},{"key":"1125_CR273","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/HYPERTENSIONAHA.123.21358","volume":"81","author":"ND Camarda","year":"2024","unstructured":"Camarda, N. D., Ibarrola, J., Biwer, L. A. & Jaffe, I. Z. Mineralocorticoid receptors in vascular smooth muscle: blood pressure and beyond. Hypertension 81, 1008\u20131020 (2024).","journal-title":"Hypertension"},{"key":"1125_CR274","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-physiol-042022-015223","volume":"86","author":"J Ibarrola","year":"2024","unstructured":"Ibarrola, J. & Jaffe, I. Z. The mineralocorticoid receptor in the vasculature: friend or foe? Annu. Rev. Physiol. 86, 49\u201370 (2024).","journal-title":"Annu. Rev. Physiol."},{"key":"1125_CR275","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s11255-025-04530-1","volume":"57","author":"Q-R Wang","year":"2025","unstructured":"Wang, Q.-R. & Yang, Y. Mineralocorticoid receptor antagonists promote renal immunosenescence. Int. Urol. Nephrol. 57, 3299\u20133306 (2025).","journal-title":"Int. Urol. Nephrol."},{"key":"1125_CR276","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd12050192","volume":"12","author":"S Poddi","year":"2025","unstructured":"Poddi, S. et al. Myocardial fibrosis: assessment, quantification, prognostic signification, and anti-fibrosis targets: a state-of-the-art review. J. Cardiovasc. Dev. Dis. 12, 192 (2025).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"1125_CR277","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1161\/HYPERTENSIONAHA.113.01803","volume":"63","author":"AJ Rickard","year":"2014","unstructured":"Rickard, A. J. et al. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone\/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 63, 1033\u20131040 (2014).","journal-title":"Hypertension"},{"key":"1125_CR278","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1111\/bph.15782","volume":"179","author":"CDCC Van der Heijden","year":"2022","unstructured":"Van der Heijden, C. D. C. C., Bode, M., Riksen, N. P. & Wenzel, U. O. The role of the mineralocorticoid receptor in immune cells in cardiovascular disease. Br. J. Pharmacol. 179, 3135\u20133151 (2022).","journal-title":"Br. J. Pharmacol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01125-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T13:03:59Z","timestamp":1794920639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-026-01125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":278,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1038\/s41581-026-01125-6","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"27 August 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.S.-B. and J.B.-C. declare no competing interests. F.J. received research grants from AstraZeneca and Bayer SAS, and honoraria from Bayer SAS and Boehringer Ingelheim Pharmaceuticals.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}